vs
Orthofix Medical Inc.（OFIX）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Rocket Lab Corp的1.2倍（$219.9M vs $179.7M），Orthofix Medical Inc.净利率更高（-1.0% vs -29.5%，领先28.4%），Rocket Lab Corp同比增速更快（35.7% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $-114.2M），过去两年Rocket Lab Corp的营收复合增速更高（39.2% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
OFIX vs RKLB — 直观对比
营收规模更大
OFIX
是对方的1.2倍
$179.7M
营收增速更快
RKLB
高出33.7%
2.0%
净利率更高
OFIX
高出28.4%
-29.5%
自由现金流更多
OFIX
多$131.0M
$-114.2M
两年增速更快
RKLB
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $179.7M |
| 净利润 | $-2.2M | $-52.9M |
| 毛利率 | 71.1% | 38.0% |
| 营业利润率 | 0.2% | -28.4% |
| 净利率 | -1.0% | -29.5% |
| 营收同比 | 2.0% | 35.7% |
| 净利润同比 | 92.4% | -1.1% |
| 每股收益（稀释后） | $-0.05 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXRKLB
| Q4 25 | $219.9M | $179.7M | ||
| Q3 25 | $205.6M | $155.1M | ||
| Q2 25 | $203.1M | $144.5M | ||
| Q1 25 | $193.6M | $122.6M | ||
| Q4 24 | $215.7M | $132.4M | ||
| Q3 24 | $196.6M | $104.8M | ||
| Q2 24 | $198.6M | $106.3M | ||
| Q1 24 | $188.6M | $92.8M |
净利润OFIXRKLB
| Q4 25 | $-2.2M | $-52.9M | ||
| Q3 25 | $-22.8M | $-18.3M | ||
| Q2 25 | $-14.1M | $-66.4M | ||
| Q1 25 | $-53.1M | $-60.6M | ||
| Q4 24 | $-29.1M | $-52.3M | ||
| Q3 24 | $-27.4M | $-51.9M | ||
| Q2 24 | $-33.4M | $-41.6M | ||
| Q1 24 | $-36.0M | $-44.3M |
毛利率OFIXRKLB
| Q4 25 | 71.1% | 38.0% | ||
| Q3 25 | 72.2% | 37.0% | ||
| Q2 25 | 68.7% | 32.1% | ||
| Q1 25 | 62.8% | 28.8% | ||
| Q4 24 | 69.0% | 27.8% | ||
| Q3 24 | 68.7% | 26.7% | ||
| Q2 24 | 67.8% | 25.6% | ||
| Q1 24 | 67.5% | 26.1% |
营业利润率OFIXRKLB
| Q4 25 | 0.2% | -28.4% | ||
| Q3 25 | -8.3% | -38.0% | ||
| Q2 25 | -7.9% | -41.3% | ||
| Q1 25 | -25.2% | -48.3% | ||
| Q4 24 | -5.3% | -38.9% | ||
| Q3 24 | -9.6% | -49.5% | ||
| Q2 24 | -12.5% | -40.7% | ||
| Q1 24 | -15.6% | -46.4% |
净利率OFIXRKLB
| Q4 25 | -1.0% | -29.5% | ||
| Q3 25 | -11.1% | -11.8% | ||
| Q2 25 | -6.9% | -46.0% | ||
| Q1 25 | -27.4% | -49.5% | ||
| Q4 24 | -13.5% | -39.5% | ||
| Q3 24 | -13.9% | -49.6% | ||
| Q2 24 | -16.8% | -39.2% | ||
| Q1 24 | -19.1% | -47.7% |
每股收益（稀释后）OFIXRKLB
| Q4 25 | $-0.05 | $-0.09 | ||
| Q3 25 | $-0.57 | $-0.03 | ||
| Q2 25 | $-0.36 | $-0.13 | ||
| Q1 25 | $-1.35 | $-0.12 | ||
| Q4 24 | $-0.76 | $-0.11 | ||
| Q3 24 | $-0.71 | $-0.10 | ||
| Q2 24 | $-0.88 | $-0.08 | ||
| Q1 24 | $-0.95 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $1.0B |
| 总债务越低越好 | — | $152.4M |
| 股东权益账面价值 | $450.0M | $1.7B |
| 总资产 | $850.6M | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.09× |
8季度趋势，按日历期对齐
现金及短期投资OFIXRKLB
| Q4 25 | $82.0M | $1.0B | ||
| Q3 25 | $62.9M | $976.7M | ||
| Q2 25 | $65.6M | $688.1M | ||
| Q1 25 | $58.0M | $428.4M | ||
| Q4 24 | $83.2M | $419.0M | ||
| Q3 24 | $30.1M | $442.4M | ||
| Q2 24 | $26.4M | $496.8M | ||
| Q1 24 | $27.0M | $492.5M |
总债务OFIXRKLB
| Q4 25 | — | $152.4M | ||
| Q3 25 | $157.2M | $347.0M | ||
| Q2 25 | $157.0M | $346.5M | ||
| Q1 25 | $156.9M | $345.9M | ||
| Q4 24 | $157.0M | $345.4M | ||
| Q3 24 | $118.5M | $61.2M | ||
| Q2 24 | $118.0M | $64.2M | ||
| Q1 24 | $118.2M | $66.8M |
股东权益OFIXRKLB
| Q4 25 | $450.0M | $1.7B | ||
| Q3 25 | $442.5M | $1.3B | ||
| Q2 25 | $458.3M | $688.5M | ||
| Q1 25 | $458.3M | $431.3M | ||
| Q4 24 | $503.1M | $382.5M | ||
| Q3 24 | $525.9M | $419.8M | ||
| Q2 24 | $546.0M | $455.2M | ||
| Q1 24 | $570.3M | $478.9M |
总资产OFIXRKLB
| Q4 25 | $850.6M | $2.3B | ||
| Q3 25 | $832.6M | $2.2B | ||
| Q2 25 | $837.2M | $1.6B | ||
| Q1 25 | $823.1M | $1.3B | ||
| Q4 24 | $893.3M | $1.2B | ||
| Q3 24 | $867.9M | $1.2B | ||
| Q2 24 | $882.0M | $1.2B | ||
| Q1 24 | $906.0M | $1.2B |
负债/权益比OFIXRKLB
| Q4 25 | — | 0.09× | ||
| Q3 25 | 0.36× | 0.27× | ||
| Q2 25 | 0.34× | 0.50× | ||
| Q1 25 | 0.34× | 0.80× | ||
| Q4 24 | 0.31× | 0.90× | ||
| Q3 24 | 0.23× | 0.15× | ||
| Q2 24 | 0.22× | 0.14× | ||
| Q1 24 | 0.21× | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $-114.2M |
| 自由现金流率自由现金流/营收 | 7.6% | -63.6% |
| 资本支出强度资本支出/营收 | 4.9% | 27.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $-321.8M |
8季度趋势，按日历期对齐
经营现金流OFIXRKLB
| Q4 25 | $27.7M | $-64.5M | ||
| Q3 25 | $12.4M | $-23.5M | ||
| Q2 25 | $11.6M | $-23.2M | ||
| Q1 25 | $-18.4M | $-54.2M | ||
| Q4 24 | $23.7M | $-2.4M | ||
| Q3 24 | $11.7M | $-30.9M | ||
| Q2 24 | $9.0M | $-13.0M | ||
| Q1 24 | $-18.6M | $-2.6M |
自由现金流OFIXRKLB
| Q4 25 | $16.8M | $-114.2M | ||
| Q3 25 | $2.5M | $-69.4M | ||
| Q2 25 | $4.5M | $-55.3M | ||
| Q1 25 | $-25.1M | $-82.9M | ||
| Q4 24 | $15.2M | $-23.9M | ||
| Q3 24 | $6.3M | $-41.9M | ||
| Q2 24 | $-360.0K | $-28.3M | ||
| Q1 24 | $-29.1M | $-21.8M |
自由现金流率OFIXRKLB
| Q4 25 | 7.6% | -63.6% | ||
| Q3 25 | 1.2% | -44.8% | ||
| Q2 25 | 2.2% | -38.3% | ||
| Q1 25 | -13.0% | -67.6% | ||
| Q4 24 | 7.0% | -18.1% | ||
| Q3 24 | 3.2% | -40.0% | ||
| Q2 24 | -0.2% | -26.7% | ||
| Q1 24 | -15.4% | -23.5% |
资本支出强度OFIXRKLB
| Q4 25 | 4.9% | 27.6% | ||
| Q3 25 | 4.8% | 29.6% | ||
| Q2 25 | 3.5% | 22.2% | ||
| Q1 25 | 3.5% | 23.4% | ||
| Q4 24 | 4.0% | 16.3% | ||
| Q3 24 | 2.7% | 10.5% | ||
| Q2 24 | 4.7% | 14.4% | ||
| Q1 24 | 5.6% | 20.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
